Pfizer and Valneva Lyme vaccine candidate shows more than 70% efficacy in Phase 3 VALOR trial
Apr 20, 2026
Pfizer and Valneva said their investigational Lyme disease vaccine candidate showed more than 70% efficacy in the phase 3 VALOR trial. Pfizer plans regulatory submissions after the study, which reported no safety concerns at the time of analysis.